Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week

Welcome to the Cannabis Countdown, the Legal Marijuana Industry’s Number One Curated Weekly News Recap.

In This Week’s Edition, We Recap and Countdown the Top 10 Cannabis and Psychedelic Stock News Stories for the Week of February 22nd – 28th, 2021.

Without further ado, let’s get started.

Yahoo Finance readers, please click here to view the full article.

10. Red White & Bloom to Enter Third Largest U.S. Cannabis Market With Acquisition of Acreage Holdings’ Florida Operations

Florida’s Cannabis Market is the Third-Largest in the U.S., With 2020 Medical Marijuana Sales Exceeding $1.2 Billion

Red White & Bloom RWBYF announced that the company has struck a deal with Acreage Holdings ACRGF to acquire its Florida operations. Upon closing of the deal, RWB will have operations or brands in 6 of the top 10 U.S. states, which generated combined revenue of over $8.8 billion last year.

READ FULL RWB ARTICLE

9. Investing $1,000 in These 2 Psychedelic Stocks is an Absurdly Smart Move

The Buzz Surrounding Psychedelic Therapies is Only Going to Grow Over Time

If you feel that missed out on the cannabis stock bonanza of the last few years, don’t fret. There’s another upcoming opportunity that’s shaping up to be even bigger: psychedelics. Even though psychedelic therapies are still in their infancy, I think there are already a few promising Psychedelic Stocks, such as Compass Pathways CMPS and MindMed MMEDF that are worth a $1,000 investment.

READ FULL PSYCHEDELIC STOCKS ARTICLE

8. Cannabis Earnings Roundup: Financials From the Big 4 Canadian LPs, Do the Recent Quarterly Results Justify the Lofty Share Prices?

Following the Cannabis Sector’s Meteoric Rise to Start the New Year, the Big 4 Canadian LPs Have Each Reported Quarterly Earnings

As a result, Cannabis investors have had the opportunity to access the up to date fundamentals of each company and determine if top Canadian Pot Stocks Aphria APHACanopy Growth CGCAurora Cannabis ACB and Cronos Group CRON are deserving of their current lofty share prices.

READ FULL CANNABIS EARNINGS ARTICLE

7. Field Trip Health Announces Upsize to Previously Announced Bought Deal Public Offering

Field Trip Intends to Use the Net Proceeds From the Offering for the Development of the Company’s FT-104 Novel Psychedelic Development Program, the Opening of New Field Trip Health Centers, and for Working Capital and General Corporate Purposes

Field Trip Health FTRPF announced that, due to strong demand, it has agreed with a syndicate of underwriters led by Bloom Burton Securities, to increase the size of its previously announced $50,000,015 bought deal offering. Pursuant to the upsized deal terms, the underwriters have agreed to purchase, on a bought deal basis, 12,750,000 common shares of Field Trip, at a price of $6.50, for aggregate gross proceeds of $82,875,000.

READ FULL FIELD TRIP ARTICLE

6. Wrigley Chewing Gum Heir to Take Cannabis MSO Parallel Public Via $1.9 Billion Deal

Chewing Gum Heir William “Beau” Wrigley Jr., the CEO of Atlanta-Based Parallel, Struck a Mammoth Deal With an Entertainment Mogul to Take the Cannabis Multi-State Operator Public Through a Transaction That Values the Company at $1.9 Billion

Ceres Acquisition Corp. – a special purpose acquisition company (SPAC) co-founded by Scott “Scooter” Braun – will buy Parallel, allowing the new company to go public by taking on Ceres’ listing on Canada’s NEO Exchange.

READ FULL WRIGLEY MSO ARTICLE

5. MindMed Closes Acquisition of HealthMode, a Leading Machine Learning Digital Medicine Company

The Acquisition Will Help MindMed Build a Full Stack Digital Mental Health Platform for Psychedelic Medicines

MindMed MMEDF reported that it has closed the previously announced acquisition of HealthMode, a digital medicine and therapeutics startup that uses Artificial Intelligence (AI)-enabled digital measurement to increase the precision and speed of clinical research and patient monitoring. MindMed also announced that ex-Pfizer PFE Digital Medicine Executive Dr. Daniel R. Karlin and former Google AI/ML industry veteran Bradford Cross were added to the company’s executive team.

READ FULL MINDMED ARTICLE

4. Investors Have Been Flocking to This U.S. Cannabis ETF

It Only Took Six Months for the Newest Cannabis ETF to Reach $1 Billion in Assets

On Tuesday, AdvisorShares announced its AdvisorShares Pure U.S. Cannabis ETF MSOS crossed the threshold, making it just the second Cannabis ETF to reach the mark. ETFMG Alternative Harvest ETF MJ is the other.

READ FULL CANNABIS ETF ARTICLE

3. Liberty Health Sciences Shareholders Overwhelmingly Approve Acquisition By Ayr Wellness

Shareholders Representing 57% of Issued and Outstanding Shares Voted and 95% Voted in Favour of the Transaction

Ayr Strategies AYRSF, a leading vertically integrated cannabis multi-state operator, and Liberty Health LHSIF announce at a special meeting, Liberty security holders voted overwhelmingly in favour of the proposed acquisition of Liberty shares by Ayr in a transaction originally announced on December 22, 2020.

READ FULL AYR ARTICLE

2. MindMed Looks Bullish on Growing Acceptance of Psychedelics

MindMed’s Stock is Up 937% Since March 2020 But it’s Just Getting Started

MindMed MMEDFis one of the best Psychedelic Stocks out there. The excitement around the medicinal potential of Psilocybin and other Psychedelics like kratom has helped put MindMed into the spotlight and fuel strong capital appreciation.

READ FULL MMED STOCK ARTICLE

1. Creso Pharma Inks Deal to Enter U.S. Cannabis Market With Established Partner

The American Cannabis Market is a Major Growth Opportunity for Creso Pharma and its Planned Deal With CERES Natural Remedies Will Help the Company Establish a U.S. Presence Ahead of Likely Federal Legalization

Creso Pharma COPHF announced that it has executed a non-binding letter of intent (LOI) with leading CBD and plant-based remedies provider CERES Natural Remedies to distribute and sell Creso’s range of CBD and hemp animal health products in the USA. CERES’ operating business, High Fidelity is Vermont’s largest independent cannabis company and through its established footprint, has generated over USD $35 million in revenue since 2013.

READ FULL CRESO PHARMA ARTICLE

Photo by Esteban Lopez on Unsplash

Posted In: Compass PathwaysMind MedicineThe Cannabis InvestorCannabisEarningsNewsPenny StocksSmall CapMarkets

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.